Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Dov Pharmaceutical completes IPO

30 Apr 2002

Executive Summary

Dov Pharmaceutical Inc. (in-licenses and develops drugs focusing on the workings of neurotransmitter receptors, ion channels and transport proteins, for treating CNS, cardiovascular, and urological disorders) netted $60.45mm in its IPO of 5mm shares at $13 each. The company had originally hoped to sell as much as $86.25mm in the offering.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By